Taxotere(docetaxel)
Beizray, Docetaxel, Docivyx, Taxotere (docetaxel) is a small molecule pharmaceutical. Docetaxel was first approved as Taxotere on 1995-11-27. It is used to treat breast neoplasms, head and neck neoplasms, melanoma, non-small-cell lung carcinoma, and ovarian neoplasms amongst others in the USA. It has been approved in Europe to treat adenocarcinoma, adenoma, breast neoplasms, head and neck neoplasms, and non-small-cell lung carcinoma amongst others. The pharmaceutical is active against tubulin beta chain.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Docetaxel, Taxotere (discontinued: Docetaxel, Taxotere)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Docetaxel
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DOCETAXEL | Accord Healthcare | N-201195 RX | 2012-04-20 | 3 products, RLD, RS |
| DOCETAXEL | Allergan | N-203551 RX | 2013-04-12 | 4 products |
| DOCETAXEL | Hospira | N-022234 RX | 2011-03-08 | 6 products, RLD, RS |
| DOCETAXEL | Sandoz | N-201525 RX | 2011-06-29 | 3 products |
| TAXOTERE | Sanofi | N-020449 RX | 2012-04-13 | 1 products, RLD |
| DOCETAXEL | Shilpa Medicare | N-205934 RX | 2015-12-22 | 3 products, RLD, RS |
Show 8 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| beizray | New Drug Application | 2025-12-15 |
| beizray beizray | New Drug Application | 2025-12-17 |
| docetaxel | ANDA | 2025-09-09 |
| docetaxel anhydrous | ANDA | 2023-07-10 |
| docivyx | New Drug Application | 2025-07-15 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J9171 | Injection, docetaxel, 1 mg |
Clinical
Clinical Trials
3065 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 86 | 372 | 211 | 27 | 79 | 723 |
| Non-small-cell lung carcinoma | D002289 | — | — | 131 | 376 | 154 | 8 | 30 | 621 |
| Prostatic neoplasms | D011471 | — | C61 | 115 | 270 | 89 | 6 | 47 | 472 |
| Neoplasms | D009369 | — | C80 | 199 | 118 | 27 | 2 | 17 | 318 |
| Lung neoplasms | D008175 | — | C34.90 | 52 | 192 | 54 | 3 | 20 | 287 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 35 | 149 | 39 | 1 | 19 | 211 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 37 | 101 | 27 | 1 | 3 | 145 |
| Adenocarcinoma | D000230 | — | — | 16 | 86 | 20 | 1 | 7 | 120 |
| Head and neck neoplasms | D006258 | — | — | 32 | 76 | 13 | 2 | 6 | 117 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 29 | 59 | 25 | 1 | 10 | 110 |
Show 14 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 15 | 60 | 25 | — | 14 | 107 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 28 | 51 | 13 | — | 6 | 91 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | 24 | 26 | — | 13 | 63 |
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | 28 | 21 | — | 13 | 62 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 16 | 28 | 10 | — | 3 | 53 |
| Sarcoma | D012509 | — | — | 21 | 31 | 7 | — | 1 | 51 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 17 | 36 | 2 | — | 2 | 50 |
| Urinary bladder neoplasms | D001749 | — | C67 | 14 | 27 | 9 | — | 3 | 47 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 8 | 22 | 15 | — | 4 | 45 |
| Recurrence | D012008 | — | — | 7 | 27 | 10 | — | 3 | 44 |
Show 89 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 19 | 14 | — | — | 2 | 24 |
| Melanoma | D008545 | — | — | 12 | 9 | — | — | 1 | 18 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 6 | — | — | 1 | 9 |
| Lymphoma | D008223 | — | C85.9 | 6 | 2 | — | — | — | 7 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 2 | 6 | — | — | 1 | 7 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 3 | 3 | — | — | — | 6 |
| Malignant pleural effusion | D016066 | — | J91.0 | 1 | 5 | — | — | — | 6 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 4 | 2 | — | — | 1 | 6 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 4 | — | — | — | 5 |
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | 2 | 2 | — | — | 1 | 5 |
Show 120 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | — | — | — | — | 3 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | 1 | 2 |
| Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | — | 2 |
| Kaposi sarcoma | D012514 | — | C46 | 2 | — | — | — | — | 2 |
| Parotid neoplasms | D010307 | EFO_0003873 | C07 | 1 | — | — | — | — | 1 |
| Medical sociology | D012962 | — | — | 1 | — | — | — | — | 1 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | 1 | — | — | — | — | 1 |
| Connective and soft tissue neoplasms | D018204 | — | — | 1 | — | — | — | — | 1 |
| Paraneoplastic syndromes | D010257 | — | — | 1 | — | — | — | — | 1 |
Show 26 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphedema | D008209 | — | Q82.0 | — | — | — | — | 2 | 2 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 2 | 2 |
| Carcinogenesis | D063646 | — | — | — | — | — | — | 1 | 1 |
| Methylation | D008745 | — | — | — | — | — | — | 1 | 1 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Breast cancer lymphedema | D000072656 | — | — | — | — | — | — | 1 | 1 |
| Taste disorders | D013651 | — | — | — | — | — | — | 1 | 1 |
| Dysgeusia | D004408 | — | R43.2 | — | — | — | — | 1 | 1 |
| Ageusia | D000370 | EFO_1001758 | — | — | — | — | — | 1 | 1 |
Show 19 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Docetaxel |
| INN | docetaxel |
| Description | Docetaxel anhydrous is a tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group. It has a role as an antineoplastic agent, a photosensitizing agent and an antimalarial. It is a tetracyclic diterpenoid and a secondary alpha-hydroxy ketone. It derives from a hydride of a taxane. |
| Classification | Small molecule |
| Drug class | antineoplastics, taxane derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O |
Identifiers
| PDB | — |
| CAS-ID | 148408-66-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545252 |
| ChEBI ID | 59809 |
| PubChem CID | 148124 |
| DrugBank | DB01248 |
| UNII ID | 699121PHCA (ChemIDplus, GSRS) |
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Docetaxel – Eagle Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Docetaxel
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,751 documents
View more details
Safety
Black-box Warning
Black-box warning for: Beizray, Beizray beizray, Docetaxel, Docetaxel anhydrous, Docivyx
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
88,285 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use